Replies to post #749722 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

I disagree. Their market cap is over $300M and if they don’t have non dilutive funds lined up, the share price continues to go down post UK approval after a brief spike. The ongoing dilution will negate any meaningful uptick in market cap realization due to UK approval. In addition to dilution, the disappointing quarterly revenues from UK going forward will add to the pain.

Plus their cash situation and dilution will make running any new trial next to impossible. So there will be no meaningful progress on R&D either.

There are quite a few biotech companies with approved therapies but they go nowhere and ultimately go bankrupt or get sold pennies on dollar due to mismanagement. Excuses and victim mindset is not a winning strategy! This management team will never make shareholders money.

[learningcurve2020]

You guys are all the same. Always hinting you’re finally coming around only to lose it all in that final paragraph full of naive hope. 🤦‍♀️

[theorysuit]

risk/reward at the current stock price is extremely favorable.

What risk reward? They are broke and have a shit ton of debt. If this stumbles in any fashion, you lose all your money. And even if they gain UK APPROVAL, what is the path to revenue in that market?